UNSPSC 51373437: Codeine/ephedrine/guaifenesin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373437 Codeine/ephedrine/guaifenesin is a Commodity code that in recent state and local solicitations frames pharmaceutical procurement more broadly than its specific drug name suggests. Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) are both seeking generic multi-source pharmaceuticals and over-the-counter products through competitive bidding and cooperative purchasing mechanisms. The actual scope of work includes procurement of naloxone and drug deactivation systems for community health initiatives, as well as comprehensive generic pharmaceutical supply arrangements with National Drug Code specifications, Good Manufacturing Practices compliance, and Drug Supply Chain Security Act certification. Issuing bodies are county health departments and state cooperative purchasing alliances that source for multiple member jurisdictions. Neither solicitation shows explicit set-asides for disadvantaged enterprises, though both require E-Verify compliance, drug-free workplace certification, and comprehensive insurance coverage including commercial general liability and professional liability.

Geographic activity centers on Florida and Minnesota, with MMCAP's cooperative structure extending participation to Oregon and other member states. Seminole County's IFB 60459723LAS, posted June 30, 2026, solicits annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries and a response deadline of July 26, 2023. MMCAP's RFP S1070000015802, posted January 20, 2026, seeks generic multi-source pharmaceutical manufacturers to supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Both opportunities carry two-year initial terms with renewal or extension options. The MMCAP procurement weights price competitiveness at 75 percent and imposes a 3 percent administrative fee on all purchases, with performance penalties ranging from $200 to $1,500 per violation.